Insertable cardiac monitor detection of silent atrial fibrillation in candidates for percutaneous patent foramen ovale closure.
Aged
Asymptomatic Diseases
Atrial Fibrillation
/ complications
Cardiac Catheterization
Clinical Decision-Making
Electrocardiography
/ instrumentation
Female
Foramen Ovale, Patent
/ complications
Heart Rate
Humans
Male
Middle Aged
Patient Selection
Predictive Value of Tests
Progression-Free Survival
Prospective Studies
Risk Factors
Stroke
/ diagnosis
Telemetry
/ instrumentation
Time Factors
Treatment Outcome
Unnecessary Procedures
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
entrez:
29
3
2019
pubmed:
29
3
2019
medline:
29
5
2019
Statut:
ppublish
Résumé
An underlying atrial vulnerability or a preexisting misdiagnosed atrial fibrillation in some patients who are candidates for patent foramen ovale (PFO) closure may lead to an unnecessary percutaneous intervention. The aim of this work was to define paroxysmal atrial fibrillation rate, through a 6-month insertable loop-recorder monitoring, in patients over 55 years old with cryptogenic stroke and PFO. PFO closure criteria: significant right-to-left shunt and at least one high-risk feature (permanent right-to-left shunt, atrial septal aneurysm, prominent Eustachian valve, recurrent brain ischemia, previous deep vein thrombosis, thrombophilia). Insertable cardiac monitoring criteria: previous cryptogenic stroke, more than 55 years and at least one atrial fibrillation risk factor (heart failure, hypertension, age older than 65 years, diabetes, atrial runs, left atrium dilatation, left ventricle hypertrophy, pulmonary disease, thyroid disease, obesity). Atrial fibrillation detection threshold: arrhythmia duration longer than 5 min. From January 2008 to March 2017, 195 patients underwent to loop-recorder monitoring. A total of 70 (36%) patients were candidates for PFO closure. The 6-month silent atrial fibrillation rate was 11.4%. In the arrhythmia-free cohort, 28 patients (45.2%) underwent percutaneous foramen ovale closure (group A) and 34 (54.8%) were medically treated (group B). Atrial fibrillation detection rate was 14.3% in group A and 0% in group B. The 36-month atrial fibrillation-free survival was 76%. An occult preexisting atrial fibrillation may lead to unnecessary percutaneous foramen ovale closure in a significant proportion of patients. A 6-month loop-recorder monitoring may improve the patient oriented decision-making.
Identifiants
pubmed: 30921267
doi: 10.2459/JCM.0000000000000790
pii: 01244665-201905000-00004
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM